ARCA biopharma, Inc. (ABIO)
After hours:
| Previous Close | 2.4900 |
| Open | 2.4500 |
| Bid | 2.4700 x 900 |
| Ask | 2.4900 x 1400 |
| Day's Range | 2.4001 - 2.4900 |
| 52 Week Range | 1.7100 - 3.8400 |
| Volume | |
| Avg. Volume | 80,500 |
| Market Cap | 35.737M |
| Beta (5Y Monthly) | 2.20 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2830 |
| Earnings Date | Aug 02, 2022 - Aug 08, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Jacob Ma-Weaver Joins ARCA biopharma Board of Directors
WESTMINSTER, Colo., June 21, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that Jacob Ma-Weaver has joined its Board of Directors. “We are pleased to welcome Jacob Ma-Weaver, the managing member of ARCA’s largest shareholder, to our Board,” said Robert E. Conway, Chairman of ARCA’s Board of Directors. “We appreciate his participation and input as we explore and evaluate strategic options for maximizing stockholder value.” Mr. Ma-Weaver is the Managing Member of Cab
- GlobeNewswire
ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review
WESTMINSTER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that it has retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor. In April 2022, the Board of Directors established a Special Committee to explore and evaluate strategic options for maximizing stockholder value. Potential strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition, merger, business combination or
- GlobeNewswire
ARCA biopharma Announces First Quarter 2022 Financial Results
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., May 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2022 financial results and provided a corporate update. Dr. Michael Bristow, ARCA’s Pres
